Discussing a case from previous observation I have in mind an African American female approximately 44 years of age recently diagnosed with uterine cancer,
First post
Discussing a case from previous observation I have in mind an African American female approximately 44 years of age recently diagnosed with uterine cancer, has experience metastasis to bladder and kidneys. Pharmacokinetics explains the absorption and movement of drugs throughout the body and pharmacodynamics are the effects of the drug on the body. Both pharmacokinetics and pharmacodynamics relationships must be understood by the clinician. Patient safety is essential, as clinicians we must be aware of the use of medications and their side effects.
In this case of the 44-year-old female with ovarian cancer, she was receiving chemotherapy and also, she was prescribed anticoagulant therapy due to recent pulmonary embolism after being diagnosed and hospitalized with COVID-19. while taking the oral anticoagulants vaginal blood loss became an issue. Weighing the options to dissolve the pulmonary embolism with anticoagulant therapy or discontinue the anticoagulant due to vaginal bleeding. This scenario gives a valid description of the beneficial effects and possible harm caused by drug therapy.
Factors that influence pharmacokinetics with this patient are the elimination process of the anticoagulant. According to Rosenthal excretion is the movement of drugs and their metabolites throughout the body, the combination of metabolism and excretion is called elimination (Rosenthal et al., 2021).
Pharmaceutical response to the anticoagulant. The anticoagulant dissolves the pulmonary embolism, although the body’s response to the medication is causing increased vaginal bleeding. It is important for the physician to find a balance. Identifying the benefits and harm of anticoagulant therapy is vital in this patient’s case. Drugs have several effects besides the therapeutic effect and the toxic effects (Thomas et al., 2012).
A personalized care plan for this patient would consist of risk for bleeding, providing interventions such as checking stool for blood loss, use of soft bristle toothbrush, avoiding sharp objects like utensils when cooking, the risk for falls and injuries. Assessment of HCT and hemoglobin for anemia will be needed. Monitoring the amount vaginal blood loss is critical as well. Increased blood loss can lead to fatigue. The plan of care changes due to the patient’s diagnosis of cancer, she also has a weak heart and a decline in her kidney functions. These comorbidities affect the treatment options. Deciding to withhold anticoagulant therapy should be based on the patient’s risk of thrombosis and the severity of the bleeding issue with this patient (Speed et al., 2021).
Reference
Rosenthal, L. D., Burchum, J. R., & Lehne, R. A. (2021). In Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed., pp. 13-13). essay, Elsevier.
Speed, V., Patel, J. P., & Arya, R. (2021). Bleeding issues in women prescribed anticoagulation. Thrombosis Update, 5. https://doi.org/10.1016/j.tru.2021.100068
Understanding Foundational Pharmacodynamics. (2022). Australian Nursing & Midwifery Journal, 27(6), 24-26.
Second post
Among the cases I witnessed during my clinical practice about 2years ago is BN’s. BN was a 76-year-old Caucasian male that initially presented accompanied his grandson following a fall at home. He had no other underlying conditions. After examination, he was medically cleared and bruises on his elbow bandaged. He is a veteran, and his grandson, also a veteran, has visited him. During his visit, BN told him he had difficulty in sleeping, and his grandson, 26year-old GN, gave him some of his sleeping pills, zolpidem. He had been sleeping fine for three days, and although he felt groggy a bit groggy in the morning, he was glad he slept better.According to Rosenthal and Burchum (2021), age is one of the patient factors that impacts drugs’ pharmacodynamics and pharmacokinetics. Notably, older age is accompanied by a decline in organ functions that alters the pharmacokinetics and pharmacokinetic properties. Older adults are at an increased risk of drug sensitivity and variability in response. Prescribers must take into account altered pharmacokinetics and variable drug sensitivities in older adults. Still, the 2019 American Geriatrics Society Beers Criteria® identifies “Z-drugs,” among them zolpidem as drugs to avoid in older adults. The Criteria strongly recommends against the use of zolpidem due to increased risk of dependency, delirium, and falls with fractures, such as in BN’s case. The drug was discontinued. BN and his grandson were educated on the importance of consulting their care provider before taking any medication.According to Praharaj et al. (2018), initial treatment for insomnia in older adults include non-pharmacological interventions such as sleep hygiene, relaxation training, sleep restriction, and cognitive-behavioral therapy. Cognitive-behavioral therapy for insomnia (CBT-I) has been specifically developed for insomnia and incorporates both cognitive-behavioral and non-pharmacologic approaches in the treatment of insomnia. As such, a care plan in DM’s would include discontinuation of zolpidem and referral to a CBT-I therapist.
ReferencesBy the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel (2019). American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society, 67(4), 674-694. https://doi.org/10.1111/jgs.15767Praharaj, S. K., Gupta, R., & Gaur, N. (2018). Clinical Practice Guideline on Management of Sleep Disorders in the Elderly. Indian journal of psychiatry, 60(Suppl 3), S383-S396. https://doi.org/10.4103/0019-5545.224477Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.) St. Louis, MO: CORE SKILL: applying ADME to a SPECIFIC patient, and explaining why the same dose behaves differently in different bodies. The assignment wants a personalized plan, not a textbook recital.
PHARMACOKINETICS — what the BODY does to the DRUG:
— ABSORPTION: route, bioavailability, FIRST-PASS METABOLISM (oral drugs traverse the liver before reaching systemic circulation — which is why IV, sublingual, and transdermal routes bypass it and require different doses). GI factors: pH, motility, food, gastric surgery, emesis.
— DISTRIBUTION: volume of distribution; PROTEIN BINDING (albumin) — and here is the clinically loaded point: in hypoalbuminemia (malnutrition, liver disease, nephrotic syndrome, cancer cachexia), the FREE (active) fraction of highly protein-bound drugs rises, so a “normal” total drug level can conceal toxicity. Phenytoin and warfarin are the classic examples. Also: the blood-brain barrier, lipophilicity, and body composition (obesity and aging increase fat mass, prolonging the effect of lipophilic drugs like diazepam).
— METABOLISM: CYP450 enzymes, phase I (oxidation) and phase II (conjugation). INDUCERS (carbamazepine, rifampin, phenytoin, St. John’s wort — an OTC/herbal that patients don’t report unless asked) lower levels of co-administered drugs; INHIBITORS (fluoxetine, paroxetine, ketoconazole, and grapefruit juice, which inhibits intestinal CYP3A4) raise them. PROdrugs require metabolism to become active — CODEINE must be converted by CYP2D6 to morphine, so ULTRARAPID 2D6 metabolizers can achieve toxic morphine levels (this is why codeine is contraindicated in children post-tonsillectomy and in breastfeeding mothers — there were infant deaths) while POOR metabolizers get no analgesia at all. That single example demonstrates pharmacogenomics, prodrug metabolism, and polymorphism at once, and it is worth building a paper around.
— EXCRETION: renal (estimate with eGFR/creatinine clearance — and note that serum creatinine ALONE is a poor guide in the elderly and in low-muscle-mass patients, because low muscle mass produces a deceptively normal creatinine despite reduced renal function), hepatic/biliary.
PHARMACODYNAMICS — what the DRUG does to the BODY: receptor binding, agonist/antagonist/partial agonist, therapeutic index, dose-response, potency vs. efficacy, tolerance, and receptor up/down-regulation.
PATIENT FACTORS TO ADDRESS EXPLICITLY (the rubric requires them): AGE (neonates — immature enzymes and reduced protein binding; elderly — reduced renal and hepatic clearance, altered body composition, polypharmacy); GENDER; GENETICS (CYP2D6/2C19 polymorphisms, HLA-B*1502); PATHOPHYSIOLOGY (renal impairment, hepatic impairment, heart failure reducing perfusion, cancer cachexia); BEHAVIOR (adherence, alcohol, tobacco — which INDUCES CYP1A2 — diet, herbal supplements).
FOR THE CASE (e.g., the patient with metastatic cancer): trace the specific mechanism — hepatic metastases impair metabolism; renal metastases impair excretion; cachexia lowers albumin and raises free drug fraction; nausea/vomiting impairs oral absorption. Then state the CONCRETE PLAN CHANGE: dose reduction, alternate route, extended interval, therapeutic drug monitoring, avoidance of high-protein-bound or hepatically cleared agents.
Collepals.com Plagiarism Free Papers
Are you looking for custom essay writing service or even dissertation writing services? Just request for our write my paper service, and we'll match you with the best essay writer in your subject! With an exceptional team of professional academic experts in a wide range of subjects, we can guarantee you an unrivaled quality of custom-written papers.
Get ZERO PLAGIARISM, HUMAN WRITTEN ESSAYS
Why Hire Collepals.com writers to do your paper?
Quality- We are experienced and have access to ample research materials.
We write plagiarism Free Content
Confidential- We never share or sell your personal information to third parties.
Support-Chat with us today! We are always waiting to answer all your questions.
